IgA nephropathy trials in China

In China 53 Also abroad 92

53 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Where
Beijing, Xi’an
Age
2 years to 18 years
People
28 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07498335
Phase 3Taking people
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Where
Baotou, Beijing, Changping, Changsha, Chengdu, Guangdong, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Yibin, Zhuhai
Age
18 years and over
People
347 worldwide
Run by
Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00
No phaseNot yet taking people in China
MYTP01 for Immune-Mediated Diseases
Where
Hangzhou
Age
18 years to 65 years
People
160
Run by
Zhejiang Provincial People's Hospital
See details and how to joinNCT07901764
Phase 2Taking people
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Where
Beijing
Age
18 years to 75 years
People
52
Run by
Kira Pharmacenticals (US), LLC.
See details and how to joinNCT05517980
Phase 4Not yet taking people in China
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
Where
Shanghai
Age
18 years to 70 years
People
20
Run by
Ruijin Hospital
See details and how to joinNCT07888335
Phase 2Taking people
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Where
Beijing, Shanghai
Age
18 years and over
People
32 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00
Phase 1Not yet taking people in China
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Where
Beijing
Age
18 years to 65 years
People
100
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07886476
Phase 3Taking people
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Where
Beijing, Cangzhou, Chengdu, Daqing, Fuyang, Fuzhou, Guangzhou, Guiyang, Hefei, Hong Kong, Jinan, Jinhua, Lanzhou, Luoyang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Yantai, Yichang, Zhongshan
Age
18 years and over
People
454 worldwide
Run by
Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00
Phase 3Taking people
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Where
Beijing, Changchun, Changsha, Guangzhou, Luoyang, Ningbo, Qingdao, Shanghai, Shenzhen, Taiyuan, Ürümqi, Wenzhou, Xian, Yinchuan, Zhengzhou
Age
18 years to 100 years
People
540 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00
No phaseTaking people
To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
Where
Beijing
Age
18 years to 75 years
People
374
Run by
Hong Zhang
See details and how to joinNCT07822100
No phaseTaking people
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Where
Guangzhou
Age
14 years and over
People
10,000
Run by
Sun Yat-sen University
See details and how to joinNCT03001947
No phaseTaking people
Correlation of Microbiome and Metabonomics With IgA Nephropathy
Where
Guangzhou, Guanzhou
Age
16 years to 65 years
People
600
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT05190848
Early phase 1Not yet taking people in China
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Where
Shanghai
Age
18 years to 75 years
People
30
Run by
Grit Biotechnology
See details and how to joinNCT07389499
Phase 3Taking people
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Where
Beijing, Hangzhou
Age
2 years to 18 years
People
31 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06994845
Phase 2Taking people
Chinese Adults With Kidney Disease
Where
Baotou, Beijing, Guiyang, Shandong, Shanghai, Shenzhen, Wuxi, Yantai, Zhengzhou
Age
18 years and over
People
30
Run by
ADARx Pharmaceuticals, Inc.
See details and how to joinNCT07522099
Phase 4Taking people
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
Where
Guangzhou
Age
18 years to 75 years
People
288
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT07604311
No phaseTaking people
The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
Where
Shanghai
People
2,000
Run by
Ruijin Hospital
See details and how to joinNCT04858724
No phaseNot yet taking people in China
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
Where
Guangdong
Age
18 years to 65 years
People
24
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT07746453
Phase 2Taking people
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
Where
Beijing, Tianjin
Age
18 years to 75 years
People
45
Run by
Everest Medicines (China) Co.,Ltd.
See details and how to joinNCT07614477
Early phase 1Taking people
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Where
Shanghai
Age
18 years to 75 years
People
96
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07203404
Phase 3Taking people
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Where
Beijing, Shanghai
Age
2 years to 18 years
People
36 worldwide
Run by
Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07024563 · EU 2024-520167-13-00
Phase 2Not yet taking people in China
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
Where
Beijing
Age
18 years and over
People
60
Run by
Qilu Pharmaceutical Co., Ltd.
See details and how to joinNCT07730632
Phase 2Taking people
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
Where
Beijing
Age
18 years and over
People
380
Run by
Chengdu Suncadia Medicine Co., Ltd.
See details and how to joinNCT07582133
Early phase 1Not yet taking people in China
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
Where
Hangzhou, Nanjing
Age
5 years to 20 years
People
30
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07674147
Phase 2Taking people
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
Where
Beijing
People
73
Run by
Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07616700